Novo Nordisk suspends heart drug trials

Novo Nordisk announced that it has prematurely halted two Phase 3 trials of its experimental drug Ziltivekimab, which targets inflammation and is directed against the IL-6 protein. The decision was based on data indicating that the drug is unlikely to meet the desired goals in treating heart failure. This conclusion came after both trials failed to produce significant results similar to a previous unsuccessful study, leading to a roughly 10% decline in the company's stock price since July. The two trials were designed to assess the drug's effect on the duration of heart failure episodes and its impact on patients' quality of life. However, the results showed that the drug was ineffective in reducing the risk of cardiovascular events or improving overall patient health. The later stages of Ziltivekimab development have faced setbacks, especially after the ZEUS trial failed to achieve its primary endpoints. This has diminished the likelihood that the drug will yield beneficial results for treating chronic heart issues and inflammation.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل